玉屏风颗粒结合枸地氯雷他定片治疗过敏性鼻炎临床研究

目的 评价玉屏风颗粒结合枸地氯雷他定片治疗过敏性鼻炎的疗效.方法 将符合入选标准的112例过敏性鼻炎患者按就诊顺序随机分为2组,每组56例.对照组口服枸地氯雷他定片,观察组在对照组基础上口服玉屏风颗粒.2组均治疗4周,随访6个月.分别于治疗前后评估中医症状积分,采用化学免疫发光法检测IgE水平,采用ELISA法检测血管细胞黏附分子-1(vascular cell adhesion molecule-1,VCAM-1)、IL-4、IL-10、白细胞三烯B4(leukotrienes B4,LTB4),评价临床疗效,记录随访期间的复发率.结果 观察组总有效率为94.6%(53/56)、对照组为80.4%(45/56),2组比较差异有统计学意义(Z=-3.254,P<0.01).治疗后,观察组流鼻涕[(1.2±0.1)分比(2.0±0.2)分,t=6.420]、鼻部瘙痒[(1.2±0.3)分比(1.7±0.3)分,t=7.003]、打喷嚏[(0.8±0.1)分比(1.3±0.1)分,t=6.716]、鼻塞[(1.1±0.1)分比(1.6±0.3)分,t=7.256]积分低于对照组(P<0.05);观察组血清IgE[(114.48±9.85)IU/ml比(130.64±10.51)IU/ml,t=6.994]、VCAM-1[(512.56±13.84)μg/L比(624.98±7.06)μg/L,t=7.803]水平低于对照组(P<0.05);观察组血清IL-4[(16.25±1.53)ng/L比(22.38±3.16)ng/L,t=5.458]、IL-10[(15.98±2.43)ng/L比(21.82±1.75)ng/L,t=6.149]、LTB4[(59.14±0.96)ng/L比(67.46±3.04)ng/L,t=5.342]水平低于对照组(P<0.05).随访6个月,观察组复发率为5.66%(3/53)、对照组为26.67%(12/45),2组比较差异有统计学意义(χ2=8.284,P=0.004).结论 玉屏风颗粒结合枸地氯雷他定片可有效改善过敏性鼻炎患者的临床症状,调节免疫功能,减少疾病复发.

Yupingfeng granule combined with citric acid and Desloratadine Citrate Disodium tablets in the treatment of allergic rhinitis and its effects of immune function

Objective To investigate the effect ofYupingfeng granule combined with Desloratadine Citrate Disodium tablets on the clinical efficacy and immune function in patients with allergic rhinitis.Methods A total of 112 patients with allergic rhinitis were randomly divided into two groups according to their order of treatment. The patients in the control group (n=56) were treated with Desloratadine Citrate Disodium tablets, and the patients in the experimental group (n=56) were treated withYupingfeng granule and Desloratadine Citrate Disodium tablets. The efficacy of clinical, the rate of adverse reaction, the improvement of immune and the rate of recurrence were compared between the two groups. Results The total effective rate of the experimental group was 94.64%, it is higher than the control group 85.71%, and the difference was statistically significant (Z=-3.254,P<0.01). After the treatment, runny nose (1.2 ± 0.1vs. 2.0 ± 0.2,t=6.420), nasal itching (1.2 ± 0.3vs. 1.7 ± 0.3,t=7.003), sneezing (0.8 ± 0.1vs. 1.3 ± 0.1,t=6.716), stuffy nose (1.1 ± 0.1vs. 1.6 ± 0.3,t=7.256)scores in the experimental group were significantly lower than those in the control group (P<0.05). There was no significant difference in the total IgE (114.48 ± 9.85 IU/mlvs. 130.64 ± 10.51 IU/ml,t=6.994) and VCAM-1(512.56 ± 13.84 μg/Lvs. 624.98 ± 7.06 μg/L,t=7.803) between the two groups (P<0.05). The levels of IL-4(16.25 ± 1.53 ng/Lvs. 22.38 ± 3.16 ng/L,t=5.458), IL-10 (15.98 ± 2.43 ng/Lvs. 21.82 ± 1.75 ng/L, t=6.149), LTB4 (59.14 ± 0.96 ng/Lvs. 67.46 ± 3.04 ng/L,t=5.342) in the experimental group were significantly lower than those in the control group (P<0.05). Six-month after the treatment, the relapse rate of the experimental group was 5.36%, while the control group was 16.07%, and the difference between two groups were significant (P<0.05).Conclusions The combination ofYupingfeng granule and Desloratadine Citrate Disodium tablets in the treatment of allergic rhinitis can significantly improve the clinical symptoms, adjust the immune function and reduce the recurrence of the disease.